The Beauty Health Company Announces Proposed Settlement of Stockholder Derivative Action: Key Details for Investors

LONG BEACH, CA, March 6, 2026 – The Beauty Health Company (“Beauty Health” or the “Company”, Nasdaq: SKIN) has made a significant announcement regarding the resolution of pending litigation that may have substantial implications for shareholders and could impact the Company’s governance and future risk profile.

Summary of Key Developments

• Proposed Settlement of Stockholder Derivative Action: On March 3, 2026, Beauty Health notified shareholders of record as of February 20, 2026, of a proposed settlement in the consolidated stockholder derivative action pending in the Delaware Court of Chancery, known as Elstein v. Saunders et al. (In re The Beauty Health Co. Consolidated S’holder Litig.), C.A. No. 2024-0114-LWW.
• Nature of Claims: The litigation arose from allegations that current and former officers and directors breached their fiduciary duties related to the launch and disclosure of issues with the Company’s flagship product, the HydraFacial Syndeo Delivery System (“Syndeo”). Plaintiffs alleged that the Company failed to adequately disclose significant hardware and software problems with Syndeo, and instead reported positive financial results and raised guidance during the period in question. The defendants have denied all wrongdoing.
• Non-Monetary Settlement: The proposed settlement is non-monetary—there is no cash payment to shareholders—but involves the implementation of substantial corporate governance reforms. The Court has scheduled a hearing for May 13, 2026, to approve the settlement.
• Attorneys’ Fees: As part of the settlement, Beauty Health (or its insurers) will pay plaintiffs’ attorneys fees and expenses of up to \$737,500, subject to court approval.

Details of the Corporate Governance Reforms

The settlement, if approved, will require Beauty Health to implement a comprehensive set of corporate governance measures aimed at addressing the alleged oversight failures. These reforms are intended to strengthen controls and oversight regarding product launches, financial disclosures, and executive accountability. Notable reforms include:

• Appointment of a Quality Ombudsman (QO):
  • An existing employee will serve as a QO, acting as a liaison between quality control, product testing, senior management, and the board.
  • The QO must be consulted before product launches, monitor customer complaints, and recommend corrective action for material issues.
  • The QO will report regularly to the Board and is protected from dismissal or compensation reduction without approval from the Audit/Compensation Committee chair.
• Enhanced Inventory and Returns Monitoring:
  • The COO or designee will provide quarterly reports to the Board detailing inventory, sales, and returns with reasons for returns.
• Audit Committee Oversight of Financial Projections:
  • The Audit Committee Charter will be amended so the committee oversees any public financial projections, ensuring their reasonableness and completeness.
• Amended Clawback Policy:
  • A Second Amended and Restated Clawback Policy will broaden coverage to more officers, allowing the Board to recover incentive compensation in cases of fraud, reckless misrepresentation, or violations of corporate governance guidelines.
• Formalization of the Disclosure Committee:
  • The Disclosure Committee will have a formal charter, include the CFO, General Counsel, and others, and will meet at least quarterly to review and improve disclosure controls.
• Enhancements to Product Committees:
  • The Product Development and Product Review Committees will be formalized, with protocols for investigating product issues and reporting to the COO and Board.
• Direct Board Oversight and Reporting:
  • The COO will meet with the Disclosure and Product Development Committees at least quarterly and promptly report material risks to the Board.

Implications for Shareholders

• Release of Claims: If the settlement is approved, all derivative claims against current and former directors and officers relating to the allegations will be released (except for claims in a separate ongoing federal securities action and claims to enforce the settlement itself).
• Material Corporate Changes: The mandated corporate governance reforms will be in effect for at least four years, with the Company and defendants acknowledging that the litigation was a substantial factor in their adoption.
• No Direct Monetary Recovery: Shareholders will not receive a direct cash payment, but the changes are designed to improve governance, reduce future risk, and potentially enhance long-term shareholder value.
• Court Approval Pending: The settlement is subject to final approval by the Delaware Court of Chancery, with a hearing set for May 13, 2026.
• Ongoing Related Litigation: This settlement does not resolve the separate federal securities class action, which remains ongoing and could have additional financial implications for the Company.

Access to Full Documentation

Shareholders can access the full Notice of Pendency and Proposed Settlement, as well as the Stipulation of Settlement and related documents, on the Company’s website at https://www.beautyhealth.com/legal-notices. For more information, shareholders may also contact plaintiffs’ counsel or review the public files at the Delaware Court of Chancery.

Potential Impact on Share Price

This announcement is potentially price-sensitive for the following reasons:

• Risk Reduction: The settlement removes a significant legal overhang relating to alleged undisclosed product problems and governance failures, potentially reducing legal and reputational risk.
• Governance Strengthening: The mandated reforms, if effectively implemented, may improve operational oversight and investor confidence in management, which could support or lift the share price over time.
• No Immediate Financial Relief for Shareholders: The absence of a cash payout may be viewed neutrally or negatively by some shareholders seeking direct recovery; however, the focus on governance reform may be valued by long-term investors.
• Remaining Uncertainties: The ongoing federal securities class action related to similar allegations remains unresolved and could result in future financial outflows.

Conclusion

Investors should closely monitor the outcome of the May 13, 2026, settlement hearing and the Company’s implementation of the required governance reforms, as these developments may affect the Company’s risk profile, reputation, and ultimately its share price.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should review the full regulatory filings and consult their financial advisors before making investment decisions. The outcome of court approval and the potential impact on share value remain subject to future events and market interpretation.

View Beauty Health Co Historical chart here